While M&A appetite has been strong in 2026, deals are increasingly thwarted by valuation gaps, geopolitical uncertainty and greater selectivity among buyers.
Reflecting on the year, industry experts at the 2026 Jefferies Global Healthcare Conference in London, taking place 16–19 November pointed to declining successful deal closure rates across the sector.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The current geopolitical backdrop has introduced additional complexity into the dealmaking process. Head of healthcare at Downing Investment Management Mark Gross observed that there has been a “stop-start” dynamic throughout the year, where changeable macro environments have delayed or derailed decision-making.
This sentiment was echoed by Hardik Madlani, managing director of Healthcare Investment Banking at Jefferies, who expressed hope that 2027 may offer more stability. “[In the] last two years, we have seen wars, we have seen inflation, we have seen interest rates,” he said.
Dissecting the deal execution pattern further, Madlani characterised 2026 as a “year of two halves.” While corporate deal activity, particularly in the first half of year, has been strong, private equity has been subdued and selective, he explained.
Gross offered additional insight into the private sector, arguing that while there is “no shortage of capital,” investors are taking a “more discerning” approach to decision-making.
In addition, Gross partly attributed a high number of aborted processes in 2026 to a mismatch between value expectations of sellers and what buyers are prepared to pay following due diligence.
Meanwhile, biopharma dealmaking is also trending towards greater selectivity. “I don’t think we are in a market where people just buy for growth,” said Madlani. Companies are now thinking more carefully about the strategic fit and quality of acquisitions, he added.
While big pharma will continue to replenish its pipeline, companies need substantial “conviction” in the assets they are purchasing so will focus on innovation and capabilities, added Aisling Zarraga, partner at the law firm Linklaters.
Europe tells a different story
While there has been robust global biopharma M&A activity in 2026, the European perspective is “very different,” according to Arun Krishnan, vice president of corporate development at Norgine.
Uncertainty around drug pricing, fueled by introduction of the Most Favored Nation (MFN) policy in the US has had significant implications for deal volumes and value, he added.
Krishnan explained that companies are less willing to part with European rights for innovative assets in fear of the potential impact on an assets value in the US, leading to a marked decrease in licensing deals.
Looking ahead to 2027, Krishnan postulated that a mid-sized EU-focused biopharma company like Norgine will need to either “go global” or “get creative” to find pockets of “MFN-proof” deal opportunities. He highlighted rare diseases assets as exempt from MFN and vaccines as a therapeutic class with less disparity between US and EU pricing.
